Chiyuki Okuda

Kobe, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.

Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: April 14, 2018

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.

Journal: Oncotarget

Published: March 22, 2018

Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.

Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.

Journal: Pathology international

Published: July 12, 2017

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Journal: British journal of cancer

Published: April 29, 2017

Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton System.

Single nucleotide variant sequencing errors in whole exome sequencing using the Ion Proton System.

Journal: Biomedical reports

Published: April 28, 2017

Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.

Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 17, 2017

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.

Journal: Oncotarget

Published: April 12, 2017

Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures.

Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures.

Journal: In vivo (Athens, Greece)

Published: January 20, 2017

PD-L1 Expression in Patients with Non-small Cell Lung Cancer.

PD-L1 Expression in Patients with Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: January 04, 2017

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.

Journal: Cancer chemotherapy and pharmacology

Published: July 25, 2015

A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapy.

A new strategy for metachronous primary lung cancer: stereotactic body radiation therapy with concurrent chemotherapy.

Journal: Anticancer research

Published: May 13, 2015

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).

A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: March 26, 2015

Showing 1-12 of 20

Last Updated: 09/26/2026